| Description |
The data is the processed mutation data from gastrointestinal cancer patients at Peking University Cancer Hospital & Institute. All patients received immune checkpoint blockade treatment (ICB, anti-PD-1/PD-L1 antibodies alone or in combination with anti-CTLA-4 antibodies) as per standard of care. Each cohort has its own specific treatment population, and the details are as followed: (1) Jiao et al, a gastrointestinal cancer mixed ICB treatment cohort (retrospective study, NPJ Precis Oncol. 2021 May 4;5(1):36);(2) Lu et al, a recurrent or metastatic neuroendocrine tumor anti-PD-1 cohort (NCT03167853, Clin Cancer Res. 2020 May 15;26(10):2337-2345); (3) Wang et al, a dMMR/MSI-H gastrointestinal cancer mixed ICB treatment cohort (retrospective study, J Immunother Cancer. 2022 Jun;10(6):e004703); (4) Bai Y et al, a Epstein-Barr virus-associated gastric cancer mixed ICB treatment cohort (retrospective study, J Immunother Cancer. 2022 Mar;10(3):e004080) |
